News
The vision research community rallies to protect the National Eye Institute from funding cuts, emphasizing its vital role in preventing blindness and advancing treatments.
Lawrence Sincich, Ph.D. Lawrence Sincich, Ph.D., professor at the University of Alabama at Birmingham School of Optometry was ...
More people in the Surrey heartlands visited hospital for problems with their vision in 2023-24, recent figures show.
The most common vision-related referral from primary care is for patients with diabetes, Rivera said, and PCPs typically ...
Investing.com -- Clearside Biomedical Inc . (NASDAQ: CLSD) stock surged 51% after Health Canada approved the company’s XIPERE treatment for uveitic macular edema, expanding the medication’s ...
Ophthalmic Drugs Market Research, 2032 The ophthalmic drugs are the formulation that are designed for the treatment of eye diseases such as ...
InvestorsHub on MSN18h
Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal DeliveryClearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical firm pioneering therapies delivered through the suprachoroidal ...
content.api.pressassociation.io on MSN15h
More people in Sussex attend vision-related hospital appointments – as access to eye care varies significantly across EnglandMore people in Sussex visited hospital for problems with their vision in 2023-24, recent figures show. A charity that funds ...
Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback